25 unknown, 13 completed, 13 recruiting, 6 terminated. 61 Phase 2, 5 Phase 3, 1 Phase 1.
Follow Tegafur: new trials by email Literature Review of Tegafur trials Research Report on Tegafur
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Exploring the Efficacy of Ferrous Sulfate/Ferrous Succinate Combined With Serplulimab and SOX Regimen in Neoadjuvant Therapy for Gastric Cancer: A Prospective Cohort Study Ferrous succinate, Ferrous Sulfate, Serplulimab - Gastric Neoplasms | Phase 2 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 54 | 2026-09-01 | 2026-10-14 |
| Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma tegafur, Gimeracil and Oteracil Potassium Capsules, Sintilimab Placebo, Sintilimab - Resectable Gastric/Gastroesophageal Junction Adenocarcinoma | Phase 2 / Phase 3 | Recruiting | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | 720 | 2026-07-31 | 2026-08-14 |
| Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction Adenocarcinoma serplulimab, Placebo - Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma | Phase 2 | Recruiting | National Cancer Center, Japan | 136 | 2026-07-15 | 2026-11-13 |
| A Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression. Trastuzumab, Monotherapy with tegafur for stage IB gastric cancer, Stage II gastric cancer treated with the SOX or XELOX regimens - IB-II Gastric Cancer | Phase 2 | Recruiting | Xijing Hospital | 120 | 2026-07-01 | 2026-08-26 |
| Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer SOX regimen, CAPEOX regimen, PD-1 inhibitor - Gastric Adenocarcinoma, Stomach Neoplasms | Phase 2 | Recruiting | Jinbo Yue | 54 | 2025-10-01 | 2026-10-15 |
| Perioperative Therapy for HER2-negative Hepatoid Adenocarcinoma of Stomach Perioperative treatment with albumin-bound paclitaxel, oxaliplatin, tegafur,gimeracil and oteracil porassium capsules and sintilimab. - Hepatoid Adenocarcinoma of Stomach | Phase 2 | Recruiting | Peking University Cancer Hospital & Institute | 30 | 2025-09-18 | 2025-12-02 |
| Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05) Iparomlimab and Tuvonralimab, Oxaliplatin, Tegafur - Immunotherapy, Gastric Cancer (GC) | Phase 2 | Recruiting | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 40 | 2025-07-23 | 2025-09-10 |
| The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction Tislelizumab, Anlotinib, Oxaliplatin - Immunotherapy Gastroesophageal Junction | Phase 2 | Unknown | Fujian Cancer Hospital | 28 | 2024-08-01 | 2024-05-07 |
| Adjuvant Treatment With Serplulimab,Trastuzumab and SOX in the HER-2 Positive GC/GEJC Serplulimab, Trastuzumab, Oxaliplatin + Tegafur - HER2-positive Gastric Cancer | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Zhengzhou University | 42 | 2024-07-15 | 2024-06-03 |
| Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma Serplulimab, thymalfasin, Oxaliplatin - Gastric Cancer, Esophagogastric Junction Adenocarcinoma | Phase 2 | Recruiting | Zekuan Xu | 30 | 2024-06-14 | 2026-03-03 |
| PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY Tegafur - Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 45 | 2024-05-07 | 2024-07-17 |
| HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer HR070803, Oxaliplatin, Tegafur - Efficacy and Safety | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 120 | 2024-04-20 | 2024-04-25 |
| AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer Cadonilimab, Ivonescimab, XELOX - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Recruiting | Harbin Medical University | 50 | 2024-04-10 | 2024-06-27 |
| Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma Nimotuzumab, Tegafur, radiotherapy - Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 95 | 2024-03-31 | 2025-05-25 |
| Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma Adebrelimab, Apatinib, Tegafur - Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 32 | 2024-03-11 | 2026-06-04 |
| Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007) S-1, Toripalimab, Intensity-modulated radiotherapy - Locally Advanced Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | Sun Yat-sen University | 140 | 2024-03-01 | 2024-03-12 |
| A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study LM-302, Toripalimab, Capecitabine - Malignant Neoplasms of Digestive Organs | Phase 2 | Recruiting | LaNova Medicines Zhejiang Co., Ltd. | 632 | 2023-07-27 | 2026-10-19 |
| Quintuple Method for Treatment of Multiple Refractory Colorectal Liver Metastases Oxaliplatin, S1, Cetuximab - For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method | Phase 2 | Unknown | Liaoning Cancer Hospital & Institute | 100 | 2023-03-15 | 2023-03-20 |
| Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC Fruquintinib, S-1, raltitrexed - Fruquintinib, S-1 | Phase 2 | Unknown | Meng Qiu | 66 | 2023-02-20 | 2025-01-22 |
| Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer Camrelizumab, apatinib, gemcitabine, oxaliplatin, tegafur - Advanced Biliary Tract Carcinoma | Phase 2 | Active not recruiting | First Affiliated Hospital of Zhejiang University | 30 | 2022-11-01 | 2026-02-12 |
Showing 20 of 61. Sign in to see all of them.
Stomach Neoplasms (14) · Carcinoma, Hepatocellular (4) · Esophageal Squamous Cell Carcinoma (4) · Carcinoma, Non-Small-Cell Lung (3) · Colorectal Neoplasms (3) · Adenocarcinoma (2) · Breast Neoplasms (2) · Colonic Neoplasms (2) · Esophageal Neoplasms (2) · Head and Neck Neoplasms (2) · Pancreatic Neoplasms (2) · Rectal Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Adenoma, Islet Cell (1) · Biliary Tract Neoplasms (1)
The First Affiliated Hospital with Nanjing Medical University (3) · Chang Gung Memorial Hospital (2) · Chinese Academy of Medical Sciences (2) · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (2) · Fudan University (2) · Fujian Cancer Hospital (2) · National Taiwan University Hospital (2) · Sun Yat-sen University (2) · Aiping Zhou (1) · Anhui Chest Hospital (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Clinical Research Support Center Kyush (1) · Eastern Cooperative Oncology Group (1) · Eastern Hepatobiliary Surgery Hospital (1) · Eastern Network of Cancer Immunological Therapy, Japan (1)
China (31) · Taiwan (10) · Japan (4) · South Korea (3) · United States (3) · United Kingdom (2) · Egypt (1) · Puerto Rico (1)
Yihebali Chi, doctor (2) · Aiping Zhou (1) · Aiping Zhou, Doctor (1) · Ashraf Abdelaziz, MD/PhD (1) · Bin Wang (1) · Caigang Liu, doctor (1) · Chih-Hung Hsu, M.D. Ph.D. (1) · Chih-Hung Hsu, M.D.Ph.D (1) · Chunmei Bai (1) · Dae Young Zang, MD, PhD (1) · Deliang Fu (1) · Feng Wang (1) · Fuxiang Zhou, M.D. (1) · Haijiao Yan (1) · Haiping Jiang (1)
PMID 36188432, PMID 18048821, PMID 19331206, PMID 21183517, PMID 21338641, PMID 26884585, PMID 27913881, PMID 29372461, PMID 32583567, PMID 34351356, PMID 35419831, PMID 36990609, PMID 37195667, PMID 37501640, PMID 40022044, PMID 41749205